Repression of interleukin-2 mRNA translation in primary human breast carcinoma tumor-infiltrating lymphocytes.
Human breast carcinoma tumor-infiltrating lymphocytes (TIL) express activation antigens in situ indicative of ongoing immune response-CD28, CD45RO, CD69, CD71, and DR. However, interleukin 2 (IL-2) receptor was poorly expressed: CD25 was detected in only 1/24 samples and CD122 in only 2/24 samples. Furthermore, isolated breast cancer TIL were defective in proliferative response but recover when treated with recombinant IL-2. Nineteen of 24 tumor samples expressed B7-1, B7-2, and CD28 protein, showing that absence of costimulator proteins or counter ligand was not the basis for TIL proliferative deficit. Expression of IL-2 activity was not detected; however, mRNA encoding IL-2 was produced and translatable in vitro. These findings show that human breast cancer tumor-induced repression of IL-2 RNA translation is the basis of failure of TIL to express the IL-2 receptor and subsequent T cell hyporesponsiveness.
Duke Scholars
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tumor Cells, Cultured
- Receptors, Interleukin-2
- RNA, Messenger
- Protein Biosynthesis
- Lymphocytes, Tumor-Infiltrating
- Interleukin-2
- Immunology
- Humans
- Gene Expression Regulation
- Female
Citation
Published In
DOI
ISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tumor Cells, Cultured
- Receptors, Interleukin-2
- RNA, Messenger
- Protein Biosynthesis
- Lymphocytes, Tumor-Infiltrating
- Interleukin-2
- Immunology
- Humans
- Gene Expression Regulation
- Female